Stock VXRT VAXART, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Vaxart, Inc.

Equities

VXRT

US92243A2006

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-17 pm EDT 		5-day change 1st Jan Change
0.9588 USD -6.00% Intraday chart for Vaxart, Inc. +36.00% +67.39%
May. 13 Transcript : Vaxart, Inc., Q1 2024 Earnings Call, May 13, 2024
May. 13 Vaxart, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : Vaxart, Inc., Q1 2024 Earnings Call, May 13, 2024
Vaxart, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (VXRT) VAXART Reports Q1 Revenue $2.2M, vs. Street Est of $0.8M
MT
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
AQ
Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13
AQ
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
AQ
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
AQ
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Vaxart, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Transcript : Vaxart, Inc., 2023 Earnings Call, Mar 14, 2024
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
AQ
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
AQ
Vaxart Appoints Steven Lo as Chief Executive; Shares Fall
MT
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
AQ
Vaxart, Inc. Announces Chief Executive Officer Changes
CI
Vaxart, Inc. Announces Management Appointments
CI
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge
AQ
North American Morning Briefing : Stock Futures -2-
DJ
B. Riley Upgrades Vaxart to Buy From Neutral, Lifts PT to $2 From $1.50
MT
Vaxart Secures $9.3 Million Award for Phase 2b COVID-19 Pill Study
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VXRT Stock
  4. News Vaxart, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW